Novo Nordisk must face US shareholder suit over CagriSema trial
A US court declined to dismiss investor claims tied to disclosures around the weight-loss candidate's pivotal results.
DO
By Daniel Okafor · Regulatory Correspondent
Jul 28 03:00 ETSource: Reuters
The wire
- 01Reuters reports a US court will allow a shareholder lawsuit against Novo Nordisk over its CagriSema weight-loss trial to proceed.
- 02Litigation over trial communications adds legal overhang to Novo's obesity franchise at a time of intense incretin competition.
- 03Surviving a dismissal motion is not a ruling on the merits; the case still has to move through discovery and any further motions.
From the source
Read at reuters.comNovo Nordisk must face US shareholder lawsuit over CagriSema weight loss trial